series-a
Stage
1
Investors
About
Newleos Therapeutics develops next-generation oral small-molecule therapies targeting neuropsychiatric disorders such as generalized anxiety disorder, social anxiety disorder, and substance use disorders by boosting the GABA system in the amygdala to deliver calming effects without sedation or dependence.
Explore Newleos Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.